Selective inhibition of human group IIA-secreted phospholipase a 2 (hGIIA) signaling reveals arachidonic acid metabolism is associated with colocalization of hGIIA to vimentin in rheumatoid synoviocytes

Journal of Biological Chemistry

Volumn 288, Issue 21, 2013, Pages 15269-15279

  Lee, Lawrence K ^a,b,c   Bryant, Katherine J ^b   Bouveret, Romaric ^b,c   Lei, Pei Wen ^b   Duff, Anthony P ^d   Harrop, Stephen J ^b   Huang, Edwin P ^b,g   Harvey, Richard P ^b,c   Gelb, Michael H ^f   Gray, Peter P ^b,g   Curmi, Paul M ^b,e   Cunningham, Anne M ^b   Church, W Bret ^a,b   Scott, Kieran F ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c VICTOR CHANG CARDIAC RESEARCH INSTITUTE   (Australia)

^d AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION   (Australia)

^e ST VINCENT S HOSPITAL   (Australia)

^f UNIVERSITY OF WASHINGTON   (United States)

^g UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACIDS; PROTEIN-PROTEIN INTERACTIONS; SELECTIVE INHIBITION; SELECTIVE INTERROGATIONS; SIGNALING PATHWAYS; SMALL MOLECULE INHIBITOR; SYNOVIAL INFLAMMATION; X RAY CRYSTAL STRUCTURES;

CATALYST ACTIVITY; CELL CULTURE; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROTEINS; UNSATURATED FATTY ACIDS;

SIGNALING;

ARACHIDONIC ACID; PHOSPHOLIPASE A2 GROUP II; VIMENTIN;

ANIMAL CELL; ARACHIDONIC ACID METABOLISM; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME LOCALIZATION; ENZYME RELEASE; ENZYME STRUCTURE; FIBROBLAST; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; INTERNALIZATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TRANSPORT; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYNOVIOCYTE; SYNOVITIS;

EICOSANOIDS BIOSYNTHESIS; PEPTIDE INHIBITORS; PHOSPHOLIPASE A; PROTEIN DRUG INTERACTIONS; PROTEIN-PROTEIN INTERACTIONS; RHEUMATOID SYNOVIOCYTES; VIMENTIN; X-RAY CRYSTALLOGRAPHY;

ANIMALS; ARACHIDONIC ACID; ARTHRITIS, RHEUMATOID; CHO CELLS; CRICETINAE; CRICETULUS; DRUG DESIGN; ENZYME INHIBITORS; FEMALE; GROUP II PHOSPHOLIPASES A2; HUMANS; MALE; SIGNAL TRANSDUCTION; SYNOVIAL MEMBRANE; VIMENTIN;

EID: 84878224071     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.397893     Document Type: Article

References (45)

1. Yanes, O., Clark, J., Wong, D. M., Patti, G. J., Sánchez-Ruiz, A., Benton, H. P., Trauger, S. A., Desponts, C., Ding, S., and Siuzdak, G. (2010) Metabolic oxidation regulates embryonic stem cell differentiation. Nat. Chem. Biol. 6, 411-417
2. Harizi, H., Corcuff, J.-B., and Gualde, N. (2008) Arachidonic-acid- derived eicosanoids. Roles in biology and immunopathology. Trends Mol. Med. 14, 461-469
3. Funk, C. D. (2001) Prostaglandins and leukotrienes. Advances in eicosanoid biology. Science 294, 1871-1875
4. 2 research. From cells to animals to humans. Prog. Lipid Res. 50, 152-192
5. 2. Ann. Rev. Biochem. 77, 495-520
6. Zeiher, B. G., Steingrub, J., Laterre, P. F., Dmitrienko, A., Fukiishi, Y., Abraham, E., and EZZI Study Group (2005) LY315920NA/S-5920, a selective inhibitor of group IIA secretory phospholipase A2, fails to improve clinical outcome for patients with severe sepsis. Crit. Care Med. 33, 1741-1748 (Pubitemid 41153699)
7. Bradley, J. D., Dmitrienko, A. A., Kivitz, A. J., Gluck, O. S., Weaver, A. L., Wiesenhutter, C., Myers, S. L., and Sides, G. D. (2005) A randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritis. J. Rheumatol. 32, 417-423 (Pubitemid 40381410)
8. 2 enzymes. Curr. Opin. Lipidol. 21, 473-480
9. 2 in human rheumatoid fibroblast-like synoviocyte arachidonic acid metabolism. J. Biol. Chem. 286, 2492-2503
10. 2 up-regulates cyclooxygenase-2 and amplifies cytokine-mediated prostaglandins production in human rheumatoid synoviocytes. J. Immunol. 165, 2790-2797
11. 2-independent mechanisms. Biochim. Biophys. Acta 1438, 213-222
12. Singer, A. G., Ghomashchi, F., Le Calvez, C., Bollinger, J., Bezzine, S., Rouault, M., Sadilek, M., Nguyen, E., Lazdunski, M., Lambeau, G., and Gelb, M. H. (2002) Interfacial kinetic and binding properties of the complete set of human and mouse groups I, II, V, X, and XII secreted phospholipases A2. J. Biol. Chem. 277, 48535-48549 (Pubitemid 35470814)
13. 2 on short chain phosphatidylcholine-mixed micelles. Development of a spectrophotometric assay suitable for a microtiter plate reader. Anal. Biochem. 204, 190-197
14. Arnett, F. C., Edworthy, S. M., Bloch, D. A., McShane, D. J., Fries, J. F., Cooper, N. S., Healey, L. A., Kaplan, S. R., Liang, M. H., Luthra, H. S. (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31, 315-324 (Pubitemid 18091653)
15. Otwinowski, Z., and Minor, W. (1997) in Methods in Enzymology (Carter, C. W. J., and Sweet, R. M., eds) pp. 307-326, Vol. 276, Academic Press, Elsevier, Amsterdam
16. Collaborative Computational Project, Number 4 (1994) The CCP4 suite. Programs for protein crystallography. Acta Crystallogr.DBiol. Crystallogr. 50, 760-763
17. Emsley, P., and Cowtan, K. (2004) Coot. Model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126-2132 (Pubitemid 41742764)
18. Davis, I. W., Murray, L. W., Richardson, J. S., and Richardson, D. C. (2004) MOLPROBITY. Structure validation and all-atom contact analysis for nucleic acids and their complexes. Nucleic Acids Res. 32, W615-W619 (Pubitemid 38997409)
19. DeLano, W. L. (2002) The PyMOL Molecular Graphics System, DeLano Scientific, Palo Alto, CA
20. 2 in arthritis plasma using a newly developed sandwich ELISA. Br. J. Rheumatol. 31, 175-178
21. 2. Biochemistry 13, 1446-1454
22. 2 based on native peptide inhibition. J. Biol. Chem. 276, 33156-33164
23. 2 by synthetic peptides derived from the primary sequence. J. Biol. Chem. 271, 23992-23998
24. 2. Nat. Struct. Biol. 2, 458-465
25. Hansford, K. A., Reid, R. C., Clark, C. I., Tyndall, J. D., Whitehouse, M. W., Guthrie, T., McGeary, R. P., Schafer, K., Martin, J. L., and Fairlie, D. P. (2003) D-Tyrosine as a chiral precursor to potent inhibitors of human nonpancreatic secretory phospholipase A2 (IIa) with antiinflammatory activity. Chembiochem. 4, 181-185 (Pubitemid 36343173)
26. Wery, J. P., Schevitz, R. W., Clawson, D. K., Bobbitt, J. L., Dow, E. R., Gamboa, G., Goodson, T., Jr., Hermann, R. B., Kramer, R. M., and McClure, D. B. (1991) Structure of recombinant human rheumatoid arthritic synovial fluid phospholipase A2 at 2.2A resolution. Nature 352, 79-82 (Pubitemid 21896703)
27. 2 involved in the binding to M-type receptors. J. Biol. Chem. 270, 5534-5540
28. 2 from inflammatory exudate. Science 254, 1007-1010
29. 2 covalently inhibited by p-bromo-phenacyl-bromide. J. Mol. Biol. 200, 181-188
30. Magro, A. J., Takeda, A. A., Soares, A. M., and Fontes, M. R. (2005) Structure of BthA-I complexed with p-bromophenacyl bromide. Possible correlations with lack of pharmacological activity. Acta Crystallogr. D Biol. Crystallogr. 61, 1670-1677 (Pubitemid 43943127)
31. 2 modified by p-bromo-phenacyl-bromide. Toxicon 36, 875-886
32. Jain, M. K., Yu, B. Z., Rogers, J., Ranadive, G. N., and Berg, O. G. (1991) Interfacial catalysis by phospholipase A2. Dissociation constants for calcium, substrate, products, and competitive inhibitors. Biochemistry 30, 7306-7317
33. Bayburt, T., Yu, B.-Z., Lin, H.-K., Browning, J., Jain, M. K., and Gelb, M. H. (1993) Human nonpancreatic secreted phospholipase A2. Interfacial parameters, substrate specificities, and competitive inhibitors. Biochemistry 32, 573-582 (Pubitemid 23034896)
34. 2 to 1.5 Å resolution provides an insight into the catalytic mechanism. Biochemistry 41, 15468-15476
35. 2 on cell membranes. Vesicle but not heparinoid binding determines rate of fatty acid release by exogenously added enzyme. J. Biol. Chem. 273, 32142-32153
36. Boilard, E., Bourgoin, S. G., Bernatchez, C., and Surette, M. E. (2003) Identification of an autoantigen on the surface of apoptotic human T cells as a new protein interacting with inflammatory group IIA phospholipase A2. Blood 102, 2901-2909 (Pubitemid 37248863)
37. 2 in prostate cancer. Cancer Res. 64, 6934-6940
38. 2 enzymes as therapeutic targets. Expert. Opin. Ther. Targets 7, 427-440
39. 2 in immune complex-mediated arthritis. EMBO Mol. Med. 2, 172-187
40. Eriksson, J. E., Dechat, T., Grin, B., Helfand, B., Mendez, M., Pallari, H. M., and Goldman, R. D. (2009) Introducing intermediate filaments. From discovery to disease. J. Clin. Invest. 119, 1763-1771
41. Thiery, J. P., Acloque, H., Huang, R. Y., and Nieto, M. A. (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139, 871-890
42. Lahat, G., Zhu, Q. S., Huang, K. L., Wang, S., Bolshakov, S., Liu, J., Torres, K., Langley, R. R., Lazar, A. J., Hung, M. C., and Lev, D. (2010) Vimentin is a novel anti-cancer therapeutic target. Insights from in vitro and in vivo mice xenograft studies. PLoS One 5, e10105
43. 2 enzymes in cancer. Biochimie 92, 601-610
44. Gadek, T. R., and Nicholas, J. B. (2003) Small molecule antagonists of proteins. Biochem. Pharmacol. 65, 1-8 (Pubitemid 35447832)
45. Arkin, M. R., and Wells, J. A. (2004) Small-molecule inhibitors of protein-protein interactions. Progressing towards the dream. Nat. Rev. Drug Discov. 3, 301-317 (Pubitemid 38499758)